Rolla, S., De Mercanti, S. F., Bardina, V., Horakova, D., Habek, M., Adamec, I. ... Clerico, M. (2017). Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology, 313., 89-91. doi: 10.1016/j.jneuroim.2017.10.009
Rolla, Simona, et al. "Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology, vol. 313, 2017, pp. 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009
Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, Dana Horakova, Mario Habek, Ivan Adamec, Eleonora Cocco, et al. "Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology 313 (2017): 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009
Rolla, S., et al. (2017) 'Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses', Journal of Neuroimmunology, 313, pp. 89-91. doi: 10.1016/j.jneuroim.2017.10.009
Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, and sur.. Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology [Internet]. 2017 December 15 [cited 2024 November 25];313:89-91. doi: 10.1016/j.jneuroim.2017.10.009
S. Rolla, et al., "Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses", Journal of Neuroimmunology, vol. 313, pp. 89-91, December 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:242798. [Accessed: 25 November 2024]